Early Diagnostics of Alzheimer’s Disease
Studies on the Enzymatic Protein Synthesis in Order to Create the Amplification Method for Beta-Amyloid Useful in the Laboratory Diagnostics of Alzheimer’s Disease
Tech Area / Field
- MED-DID/Diagnostics & Devices/Medicine
- BIO-CGM/Cytology, Genetics and Molecular Biology/Biotechnology
3 Approved without Funding
Institute of Gerontology, Russia, Moscow
- Institute of Cell Biophysics, Russia, Moscow reg., Puschino\nState Research Center for Applied Microbiology, Russia, Moscow reg., Obolensk\nInstitute of Bioorganic Chemistry (Branch), Russia, Moscow reg., Puschino
- Vanderbilt University / Department of Pharmacology, USA, TN, Nashville\nNational Institute of Environmental Health Sciences, USA, NC, Research Triangle Park\nDuke University / Medical Center / Department of Pharmacology and Cancer Biology, USA, NH, Durham
Project summaryAlzheimer’s disease is a very dangerous neurodegenerative illness. It’s characterized by a long period of incubation and by the lack of any symptoms and early diagnostic tests. Pharmacotherapy was unsuccessful hitherto. Post-mortem histological and electron microscopic studies on brain sections of patients indicated the presence of specific beta-amyloid protein structures.
The main objectives of the project are the study on enzymatic protein synthesis in cell-free system, to create reaction for beta-amyloid protein amplification and a standard sensitive system for the enzymatic protein synthesis allowing maximal accumulation of beta-amyloid. The laboratorial diagnostics for early stages of Alzheimer’s disease would be elaborated on the basis of the protein amplification.
The specific objectives of the project can be summarized as follows:
1. To study concentration, temperature, and time dependences in cell-free system for enzymatic protein synthesis.
2. To create and develop the standard system for beta-amyloid protein amplification in a test sample and to study the effects of some key reagents on the beta-amyloid protein synthesis.
3. To study the parameters of commercial beta-amyloid formation in the standard test-system for protein amplification, and to develop incubation conditions allowing to accumulate beta-amyloid in microamount sufficient for its further identification.
4. To develop the method for identification of beta-amyloid in the standard test-system.
5. To create the animal model of Alzheimer’s disease in mice and to expand the new method for identification of beta-amyloid in animal tissues.
6. To evolve the methodology of preparing biomaterials from animals and humans for the beta-amyloid protein amplification. To carry out preclinic work-up using the method of early identification of beta-amyloid.
7. To device early laboratory diagnostics of Alzheimer’s disease and early identification of beta-amiloid, and to carry out the clinical investigation.
Project participants are qualified scientists in knowledge-intensive technologies and animal using and modeling human diseases, possess methods for cell-free protein synthesis, protein isolation and fractionation, protein identification from solutions and biological samples, pre-clinic and clinic investigations.
The International Science and Technology Center (ISTC) is an intergovernmental organization connecting scientists from Kazakhstan, Armenia, Tajikistan, Kyrgyzstan, and Georgia with their peers and research organizations in the EU, Japan, Republic of Korea, Norway and the United States.
ISTC facilitates international science projects and assists the global scientific and business community to source and engage with CIS and Georgian institutes that develop or possess an excellence of scientific know-how.